BioNTech CEO Offloads 100,000 Shares as Founders' Exit Talks Turn Testy

BioNTech CEO U?ur ?ahin has sold 100,000 ordinary shares under a June 2026 trading plan, as the company prepares to shut German sites.

U?ur ?ahin has trimmed his stake in BioNTech once again, with SEC filings showing the CEO disposed of 17,000 ordinary shares on both Thursday and Friday of last week. The disposals were executed under a trading plan adopted on June 3, 2026, in line with Rule 10b5-1 — the standard mechanism that lets executives schedule share sales at predetermined times and conditions, insulating them from any link to day-to-day business developments.

Those two tranches extend a pattern already visible in late September, when ?ahin shed 34,000 shares on the 29th and another 32,000 the following day through the same plan. Add it all up and the CEO has now parted with 100,000 ordinary shares in total.

The stock barely registered the news. BioNTech's paper changed hands at EUR 85.90 in Monday trading, a dip of 0.2%. On a pre-market basis it stood at EUR 86.10, putting it 1.8% above its 200-day moving average of EUR 84.61.

A Separation That Isn't Running Smoothly

The share sales land in the middle of a far more delicate process: the unwinding of the founders' ties to the company they built. According to a Handelsblatt report dated September 24, the separation of ?ahin and Özlem Türeci from Mainz-based BioNTech has run into friction over patents, financial resources and personnel. Both intend to leave by the end of 2026.

Their attention is expected to shift to Arife, a new Mainz-based venture focused on developing novel mRNA-based medicines. For BioNTech, the departure of its two most recognizable figures amounts to a profound rupture at the top of the organization.

German Plants on the Chopping Block

Running alongside the leadership transition are blunt operational cuts. After failing to find buyers for its German manufacturing sites, BioNTech is shutting facilities in Tübingen, Marburg and Idar-Oberstein. Tübingen is slated to wind down by the end of 2027, Marburg at the start of 2028 and Idar-Oberstein by the end of 2028. A site in Singapore is also earmarked for closure, according to Reuters.

Taken together, the measures affect as many as 1,860 positions. Management has agreed with the works council on socially acceptable arrangements and additional severance terms. The restructuring is a direct response to weaker demand now that the pandemic-era surge in business has faded.

Oncology Data Offers a Counterweight

Even as it dismantles parts of its industrial base, BioNTech is pressing ahead with its research pipeline. Roughly two weeks ago, the company and partner OncoC4 released data from the PRESERVE-003 trial of Gotistobart in previously treated squamous non-small cell lung cancer. The first stage showed a median overall survival of 18.5 months, against 10.0 months for standard chemotherapy. Progress in novel cancer therapies is viewed as a cornerstone of the company's future pipeline.

Monsanto Suit Clears an Early Hurdle

Legal troubles in the United States add another layer of uncertainty. About a week ago, a federal judge in Delaware declined motions from BioNTech, Pfizer and Moderna to dismiss claims brought by Bayer subsidiary Monsanto. The case concerns the mRNA technology used in COVID-19 vaccines. The ruling allows the plaintiffs to pursue the litigation but explicitly does not establish that any patents have been infringed.

Despite the courtroom wrangling and the announced plant closures, BioNTech shares have gained 5.6% since the start of the year.